- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Home > Press > Hawk Trade Secures Funding and Development Capital for Nanotec Industries: Nanotec Industries successfully negotiates funding for development of nano-sized treatment and imaging delivery device facility through Hawk Trade
Nanotec Industries a technology company focused on the medical applications of nanotechnology, has announced that it has been granted development capital by Tokyo-based investment fund, Hawk Trade.
The news means that the fledgling company will be able to fund the construction of a highly-anticipated new nano-testing facility which will focus on the development of nano-sized devices for the delivery of medicine or imaging materials into organs or areas of the body that have traditionally been difficult to reach.
A Hawk Trade business analyst said, "The sheer potential for this technology defies belief. Science fiction is literally being made science fact by the immensely talented people at Nanotec Industries."
A report from Nanotec Industries discusses two categories of self-assembled delivery solutions at the nano-scale level that can deploy medicines and imaging agents beyond physiological barriers that, ordinarily, they would be unable to cross. The paper's corresponding author stated that the nanoscale self-assembly instruments are complicated structures that are formed from simple parts either naturally or engineered. The complex structure of the nanoscale instruments cannot be attained easily by chemical synthesis.
According to Nanotec Industries, many biological events depend on structures that assemble or disassemble due to physiological needs and environmental variations. Natural self-assemblies, for example, proteins and viral capsids depend on weak forces whereas engineered self-assemblies utilized in nanomedicine include the micellar nanostructure and more than five categories of structural shapes.
Nanotec-Industries studied the physiochemical and structural properties and the potential applications of each structure type.
Hawk Trade says it will allow drawdown of the funds according to the project requirements and confirms that it will authorize additional funding based on further assessment of developments made by the company.
About Hawk Trade
Since our inception in 2007, Hawk Trade has focused on delivering exceptional investment performance to our clients both corporate and individual, by coupling entrepreneurial drive with deep industry expertise and robust risk management.
High net worth clients depend on our tailored innovative solutions and on seizing the right opportunities at the most optimum moment. We align ourselves with corporate clients to help them attain all of their capital market requirements.
About Nanotec Industries
Nanotec Industries is dedicated toward the advancement of our revolutionary immuno-nanoparticle technology, which is making waves within the surgical field of medicine. We are making significant progress in the disciplines of tissue regeneration and disease detection, in addition to ground-breaking research projects in the biomedical sphere.
Nanotec Industries utilizes technology at the cutting-edge of science, from research faculties renowned for their innovation around Western Europe. Our ethos however is firmly intertwined with a far more traditional approach to medicine, taking our inspiration from Asian medicinal practices that have flourished for thousands of years.
For more information, please click here
Copyright © PR Worldwide, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Controlled electron pulses November 30th, 2016
Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016